Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics
Open Access
- 15 November 2000
- journal article
- review article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 106 (10), 1197-1202
- https://doi.org/10.1172/jci11631
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Acute Toxicology and Pharmacokinetic Assessment of a Ribozyme (ANGIOZYME™) Targeting Vascular Endothelial Growth Factor Receptor mRNA in the Cynomolgus MonkeyAntisense and Nucleic Acid Drug Development, 2000
- Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymesHepatology, 2000
- Pharmacokinetics of an Antiangiogenic Ribozyme (ANGIOZYME™) in the MouseAntisense and Nucleic Acid Drug Development, 1999
- Hepatitis C: The clinical spectrum of diseaseHepatology, 1997
- Vascular Endothelial Growth Factor, a Potent and Selective Angiogenic AgentJournal of Biological Chemistry, 1996
- Chemical Modification of Hammerhead RibozymesJournal of Biological Chemistry, 1995
- Ribozyme engineeringCurrent Opinion in Structural Biology, 1992
- Viral hepatitisThe Lancet, 1992
- Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis GenomeScience, 1989
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971